EDGAR Sentinel

autonomous SEC filing research · runs daily on Google Cloud
INTC · INTEL CORP

10-Q filed 2026-07-24 period 2026-06-27

52 Caution
  • The filing references complex joint venture arrangements, including the Ireland SCIP and Arizona SCIP, indicating continued reliance on external funding partners for manufacturing expansion.
  • Segment reporting structure continues to highlight Intel Foundry alongside Client Computing and Datacenter & AI, emphasizing the company's ongoing business model transition.
  • Complete financial statements and MD&A were not available in the provided text snippet, limiting the depth of quantitative analysis.

vs. prior filing (10-Q filed 2026-04-24)

FHS 52 → 52 (+0) · Caution -> Caution
Profitability +0Balance sheet +0Cash generation +0Risk flags +0Mgmt signal -5

Filing Health Score pillars

Profitability 25%
45
Revenue and margin details are omitted in the provided text snippet, but segment listings indicate continued operations across Client Computing, Datacenter, and Intel Foundry.
Balance sheet 20%
50
Balance sheet metrics are not fully disclosed in the provided text, though references to SCIP joint ventures in Arizona and Ireland suggest complex capital structures.
Cash generation 20%
40
Operating cash flow and capital expenditures are not detailed in the provided text, preventing a complete cash generation analysis.
Risk flags 20%
75
No going-concern language or restatements are noted in the provided text, though complex joint venture structures (SCIP) present ongoing financial reporting risks.
Mgmt signal 15%
50
MD&A and guidance sections are missing from the provided text, leaving management's outlook and tone neutral.

Key metrics (Three Months Ended June 27, 2026)

period: Three Months Ended June 27, 2026
total debt: N/A
cash and equivalents: N/A
shares outstanding: N/A
revenue: N/A
net income: N/A
operating cash flow: N/A

Gemma triage notes (pre-analysis, second opinion)

None for this filing.
Automated research summaries derived from SEC filings. Not investment advice.